BioCentury | Nov 21, 2011
Clinical News

Sirolimus regulatory update

...non-infectious uveitis. Santen received worldwide rights to develop and commercialize sirolimus from MacuSight in 2010. MacuSight Inc....
BioCentury | Sep 12, 2011
Clinical News

Sirolimus regulatory update

...the indication. Santen received worldwide rights to develop and commercialize sirolimus from MacuSight in 2010. MacuSight Inc....
BioCentury | Jun 6, 2011
Company News

Otonomy management update

...Business: Other, Drug delivery, Infectious Hired: Gerald Wroblewski as COO, formerly VP of operations at MacuSight Inc. WIR...
BioCentury | Dec 13, 2010
Company News

Otonomy management update

...Drug delivery, Infectious Hired: David Weber as president, CEO and a director, formerly CEO of MacuSight Inc....
BioCentury | Dec 9, 2010
Company News

Otonomy names Weber CEO

...Weber as president, CEO and a director. He is the former CEO of ophthalmic company MacuSight Inc....
BioCentury | Oct 26, 2009
Clinical News

Perceiva sirolimus regulatory update

...FDA granted Fast Track designation to MacuSight's Perceiva to treat diabetic macular edema (DME). The extended-release...
...DME, wet age-related macular degeneration (AMD) and dry eye syndrome, with data expected in 1H10. MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...patients in a placebo-controlled, dose-ranging, U.S. Phase II trial evaluating single subconjunctival injections of Perceiva. MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...evaluating subconjunctival and intravitreal injections of Perceiva given at baseline, 2 months and 4 months. MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...a unit of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), and Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...trial evaluating 3 dosages of subconjunctivally injected Perceiva given at baseline and at 3 months. MacuSight Inc....
Items per page:
1 - 10 of 21
BioCentury | Nov 21, 2011
Clinical News

Sirolimus regulatory update

...non-infectious uveitis. Santen received worldwide rights to develop and commercialize sirolimus from MacuSight in 2010. MacuSight Inc....
BioCentury | Sep 12, 2011
Clinical News

Sirolimus regulatory update

...the indication. Santen received worldwide rights to develop and commercialize sirolimus from MacuSight in 2010. MacuSight Inc....
BioCentury | Jun 6, 2011
Company News

Otonomy management update

...Business: Other, Drug delivery, Infectious Hired: Gerald Wroblewski as COO, formerly VP of operations at MacuSight Inc. WIR...
BioCentury | Dec 13, 2010
Company News

Otonomy management update

...Drug delivery, Infectious Hired: David Weber as president, CEO and a director, formerly CEO of MacuSight Inc....
BioCentury | Dec 9, 2010
Company News

Otonomy names Weber CEO

...Weber as president, CEO and a director. He is the former CEO of ophthalmic company MacuSight Inc....
BioCentury | Oct 26, 2009
Clinical News

Perceiva sirolimus regulatory update

...FDA granted Fast Track designation to MacuSight's Perceiva to treat diabetic macular edema (DME). The extended-release...
...DME, wet age-related macular degeneration (AMD) and dry eye syndrome, with data expected in 1H10. MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...patients in a placebo-controlled, dose-ranging, U.S. Phase II trial evaluating single subconjunctival injections of Perceiva. MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...evaluating subconjunctival and intravitreal injections of Perceiva given at baseline, 2 months and 4 months. MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...a unit of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), and Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). MacuSight Inc....
BioCentury | Oct 5, 2009
Clinical News

Perceiva sirolimus: Completed Phase II enrollment

...trial evaluating 3 dosages of subconjunctivally injected Perceiva given at baseline and at 3 months. MacuSight Inc....
Items per page:
1 - 10 of 21